NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Not Recruiting

Trial ID: NCT02429804

Age - 19 Years-N/A Condition - Prostate Cancer, Prostate - Metastatic Gender - Male Accepting Healthy Volunteers - No

Purpose

This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.

Official Title

Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study

Stanford Investigator(s)

Andrei Iagaru
Andrei Iagaru

Professor of Radiology (Nuclear Medicine)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Eligibility


Inclusion Criteria:

   - Provides written informed consent

   - Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223
   dichloride)

   - Able to remain still for duration of the imaging procedure (about one hour)

Exclusion Criteria:

   - Metallic implants

View More
View Less

Intervention(s):

procedure: Contrast-enhanced Magnetic Resonance Imaging

procedure: Magnetic Resonance Imaging

procedure: Positron Emission Tomography

drug: Fludeoxyglucose F-18

drug: Fluorine F 18 Sodium Fluoride

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Omar Rutledge
650-721-4089

New Trial Alerts

©2024 Stanford Medicine